Actuarial Outpost
 
Go Back   Actuarial Outpost > Actuarial Discussion Forum > Health - Disability
FlashChat Actuarial Discussion Preliminary Exams CAS/SOA Exams Cyberchat Around the World Suggestions


Reply
 
Thread Tools Search this Thread Display Modes
  #271  
Old 07-02-2018, 12:20 PM
ShivamS's Avatar
ShivamS ShivamS is offline
Member
SOA
 
Join Date: Mar 2013
College: Yep
Favorite beer: Sweetwater Blue
Posts: 3,413
Default

Quote:
Originally Posted by twig93 View Post
Ah! So we need better disincentives. Thanks for the clarification.
Sort of. The main problem is the slight modification of the drug to extend the patent. I think that's what happened with Humira. The "paying off other companies" methodology isn't very common, as far as I know.




Here's another article: https://www.cnn.com/2018/06/29/healt...nts/index.html

Funnily enough, my problem is with this "Questcor shocked the medical community when, on August 27, 2007, it raised the price overnight from $1,600 to $23,000 a vial" more than the aggressive marketing and outreach that the new company is doing.
__________________
Spoiler:
Quote:
Originally Posted by Agadefe View Post

Physical violence as acceptable reaction or outdated masculine bravado as a positive quality is definitely not something the country should be moving towards or qualities we want to see in a President.



Reply With Quote
  #272  
Old 07-14-2018, 04:49 PM
This is my Alt This is my Alt is offline
Member
SOA
 
Join Date: Jul 2012
Posts: 2,624
Default

Yup - still completely arbitrary pricing

Pfizer to Postpone Some Drug Price Increases, After Criticism From Trump

Quote:
Originally Posted by NYTimes
WASHINGTON — Pfizer, the giant multinational drug company, said on Tuesday that it would defer some price increases, after President Trump thrashed the company in a Twitter post.

The company — whose products include Celebrex, Lipitor, Premarin, Viagra and Zoloft, as well as Ibrance, a breast cancer treatment that costs about $10,000 a month — retreated one day after Mr. Trump’s tweet.

“Pfizer & others should be ashamed that they have raised drug prices for no reason,” Mr. Trump tweeted on Monday. “They are merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. We will respond!”

On Tuesday, Mr. Trump said he was pleased to see the company backtracking.

“Pfizer is rolling back price hikes, so American patients don’t pay more,” Mr. Trump tweeted. “We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!”

At a bill-signing ceremony on May 30, Mr. Trump said major drug companies would, within two weeks, announce “voluntary massive drops in prices.” But until now, there was scant evidence of drug price cuts, and some companies continued to raise prices, seemingly oblivious to the president’s words.

Ian C. Read, the chairman and chief executive of Pfizer, said he had “an extensive discussion with President Trump” on Tuesday. As a result, he said, Pfizer will roll back price increases that took effect on July 1.

David Mitchell, the founder of Patients for Affordable Drugs, a nonprofit advocacy group, applauded the move, but said it was just a start.

“President Trump took Pfizer to the woodshed, and that’s good,” he said. “There are other companies that have also increased prices in recent months that could also use a whupping. But one-off trips to the woodshed do not fix the systemic problems we have with drug prices.”

In a Rose Garden speech two months ago, Mr. Trump unveiled a “blueprint to lower drug prices,” which included many regulatory and legislative proposals and some vague notions about how to rein in drug costs.

Mr. Read said Pfizer was postponing its price increases “to give the president an opportunity to work on his blueprint” and to “provide more access for patients.”

He said the higher prices would revert to the levels in effect last month and would stay there until “the president’s blueprint goes into effect or the end of the year, whichever is sooner.” The price freeze is likely to last six months, as the president’s most important proposals will probably require months of debate and deliberation.

“Pfizer shares the president’s concern for patients and commitment to providing affordable access to the medicines they need,” Mr. Read said.

He said the world was entering a “new era with scientific advances that will result in future breakthroughs and cures.”

But some of the most promising and effective new treatments are also among the most expensive — a fact that scares many consumers, insurers and employers who help pay the bills.
Reply With Quote
  #273  
Old 07-14-2018, 04:51 PM
This is my Alt This is my Alt is offline
Member
SOA
 
Join Date: Jul 2012
Posts: 2,624
Default

Must be nice to be a CEO at one of these companies and just increase your revenue by 10% each year through price increases
Reply With Quote
  #274  
Old 07-17-2018, 12:17 PM
ajstudies's Avatar
ajstudies ajstudies is offline
Member
SOA AAA
 
Join Date: Nov 2006
Favorite beer: root
Posts: 3,770
Default

Quote:
Originally Posted by This is my Alt View Post
Must be nice to be a CEO at one of these companies and just increase your revenue by 10% each year through price increases
Right?
__________________
Quote:
Originally Posted by campbell
There's definitely a humor diversity in the profession.
Quote:
Originally Posted by Evil Twin View Post
If there are any stray hairs around, feel free to split them while I'm gone.
Reply With Quote
  #275  
Old 07-17-2018, 12:54 PM
YetAnotherCareerChanger's Avatar
YetAnotherCareerChanger YetAnotherCareerChanger is offline
Member
CAS
 
Join Date: Jan 2014
Posts: 2,978
Default

Quote:
Originally Posted by This is my Alt View Post
Must be nice to be a CEO at one of these companies and just increase your revenue by 10% each year through price increases
IFYP.
Reply With Quote
  #276  
Old 07-19-2018, 01:21 PM
George Frankly's Avatar
George Frankly George Frankly is offline
Member
SOA AAA
 
Join Date: Aug 2011
Location: CO
Favorite beer: Sam Smith Oatmeal
Posts: 9,909
Default

Quote:
Originally Posted by This is my Alt View Post
Novartis to follow suit, per The NYT.
Reply With Quote
  #277  
Old 07-24-2018, 09:58 AM
LICENSED TO ILL's Avatar
LICENSED TO ILL LICENSED TO ILL is offline
Member
 
Join Date: Oct 2005
Posts: 734
Default

Doesn't mean insurance prices won't go up.
__________________
Spoiler:
Quote:
Originally Posted by Abelian Grape View Post
Nothing gay about mirin' another bro's gains.
Quote:
Originally Posted by campbell View Post
Want to become aware of my fist?
Quote:
Originally Posted by OddSox View Post
this might be my favorite thread on the AO
Reply With Quote
  #278  
Old 07-24-2018, 04:24 PM
mathmajor's Avatar
mathmajor mathmajor is offline
Member
SOA AAA
 
Join Date: Dec 2010
Location: Nowhere in particular
Studying for Japanese
College: B.S. Applied Math
Favorite beer: La Croix Grapefruit
Posts: 9,376
Default

Doesn't mean PBMs will allow a 10% price increase through. They still control which drugs get on formulary or don't.

Insurers in particular have very strict pharmacy controls and run at very high generic fill rates. A brand price hike on some drugs has less impact than you'd think. Bigger fish to fry.
__________________
FSA
Reply With Quote
  #279  
Old 07-24-2018, 05:36 PM
George Frankly's Avatar
George Frankly George Frankly is offline
Member
SOA AAA
 
Join Date: Aug 2011
Location: CO
Favorite beer: Sam Smith Oatmeal
Posts: 9,909
Default

Louisiana Medicaid gets creative to pay for Hep C drugs, I'll be very curious to see if this deal gets inked. It's kind of unique in that it's Medicaid, those programs are often on very limited budgets and their beneficiaries are poor and often frail. So I have to wonder if this would ever be extensible to commercial programs. Perhaps with biosims you might see a deal like this.

https://www.ajmc.com/focus-of-the-we...is-c-treatment
Reply With Quote
  #280  
Old 07-26-2018, 01:05 PM
YetAnotherCareerChanger's Avatar
YetAnotherCareerChanger YetAnotherCareerChanger is offline
Member
CAS
 
Join Date: Jan 2014
Posts: 2,978
Default

Quote:
Originally Posted by George Frankly View Post
Louisiana Medicaid gets creative to pay for Hep C drugs, I'll be very curious to see if this deal gets inked. It's kind of unique in that it's Medicaid, those programs are often on very limited budgets and their beneficiaries are poor and often frail. So I have to wonder if this would ever be extensible to commercial programs. Perhaps with biosims you might see a deal like this.

https://www.ajmc.com/focus-of-the-we...is-c-treatment
If I were Gilead I'd be concerned that the first part of the agreement would happen (lots of drugs & flat $) then someone new in the gov would cancel the deal when the tax payer's weren't "getting their money". Put some very strong language in there to hold them to the final $'s, imo.

Seems like somewhat of a risk to the state's medicaid budget if lower cost drugs with the same level of efficacy come out in the next 3 years. Not sure what level of risk there is of that happening.

Also, I've not dealt with Hep C drugs in a while... if I recall correctly Sovaldi's only effective for certain genotypes of Hep C which account for 25-30% of Hep C patients. (A quick google says Sovaldi is for genotype 2 & 3) Though looking up the other drug I remember that was the compliment to Sovalid was Harvoni and that's also made by Gilead, they use a common drug but differ in their partner drugs. So maybe it'll be a packaged deal for Hep C drugs generally? Maybe they only need 2 & 3 because the cheaper Viekira Pak covers 1 & 4?

Seems like an interesting deal, will be interesting to see if it happens or is a pipe dream.
Reply With Quote
Reply

Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


All times are GMT -4. The time now is 10:57 PM.


Powered by vBulletin®
Copyright ©2000 - 2018, Jelsoft Enterprises Ltd.
*PLEASE NOTE: Posts are not checked for accuracy, and do not
represent the views of the Actuarial Outpost or its sponsors.
Page generated in 0.24705 seconds with 11 queries